




**Contact**  
 Amos Adler M.Sc., CEO  
[amos@a4i.me](mailto:amos@a4i.me)  
<https://www.a4i.me>

## App4Independence

A4i is a validated digital patient engagement mobile application and clinical portal to scale support for people with severe mental illnesses and opioid/substance use disorders.



**Codesigned** with patients, clinicians and families.

**Scales** clinical oversight, peer support, and personalized care.

**Connects** patients to certified peer support workers and behavioral health teams.

**Monitors** for adherence and risk-related escalations to detect early signs of disengagement or relapse

A4i is a Joint Venture between Canada's largest mental health academic hospital The Centre for Addiction & Mental Health (**CAMH**) and the **MEMOTEXT** platform for co-creation of digital patient engagement.

## Traction and Evidence

**Clinical Validation:** Completed CIHR-funded clinical trials N=90 and open-ended feasibility trial showing improvements in symptoms, alliance, and psychosis related measures. published in PLOS One; predictive modelling published in Frontiers in Psychiatry.

**Real-World Implementation:** Expanded deployment across 9 Riverside University Health System sites (California); pilots active at CAMH outpatient clinics and The Royal Ottawa Mental Health Centre; Waypoint Centre, OBIO Early Adopter program completed.

**Commercial Contracts:** Secured multi-year agreements with Riverside (CA) and Waypoint Centre (ON).

**Recognition:** Scientific American "Top 10 Startups Changing Healthcare"; Larta Heal.LA cohort; \$100K TIAP award for AI.

## Value of A4i

### Key Features:

- Patented auditory hallucination detector
- AI-moderated social-media experience
- Patient self-management tools such as goal tracking, medication reminders

### Outcomes:

- Significant early improvements in several symptom domains
- Readmission reduction and \$2.5:1 ROI model proven in US behavioral health market.
- Early risk detection through AI based risk prediction of collected ambient data, sentiment and textual data to avoid rehospitalization

Regulatory (FDA) pathway towards Software as a Medical Device (SaMD)

Multiple use-cases: Psychosis related illness, Schizophrenia, Opioid/Substance Use Disorders,

## About Us

**Dr. Sean Kidd PhD. | Chief Science Officer**  
 co-director and senior scientist with the Institute for Mental Health Policy Research at CAMH

**Amos Adler M.Sc. | Chief Executive Officer**  
 12 years of digital health commercialization leadership at MEMOTEXT Corp/LLC

**Wenjia Zhou, MHI | Chief Product Officer**  
 + 6 years Medical Science Product Management

